A recent feature from CBS News examined whether Johnson & Johnson and Bayer, the makers of Xarelto, knowingly withheld certain important data for a letter to be published in the New England Journal of Medicine.
The specific claim made by lawyers for Xarelto plaintiffs in the multi-district litigation (MDL) class action lawsuit is that the defendants purposely withheld information from results published involving a Duke University analysis of drug trial results. This information relates to a blood testing device that was not functioning property. The device was being used to test patients who were on Warfarin (Coumadin), which is the traditional alternative to Xarelto. Continue reading